Farxiga extended in the US to reduce risk of cardiovascular death and hospitalisation for heart failure to a broader range of patients

AstraZeneca’s Farxiga (dapagliflozin) has been approved in the US to reduce the risk of cardiovascular (CV) death, hospitalisation for heart failure (hHF) and urgent heart failure (HF) visits in adults with HF. The approval by the Food and Drug Administration (FDA) was based on positive results from the DELIVER ...

Related Keywords

Illinois ,United States ,Chicago ,Turkey ,China ,Japan ,Cambridge ,Cambridgeshire ,United Kingdom ,Great Britain ,American ,J Geriatr Cardiol ,Astrazeneca Farxiga ,Coll Cardiol ,Astrazeneca ,Centers For Disease ,Drug Administration ,A Report From The American Heart Association ,Company On Twitter ,European Union ,National Institute Of Diabetes ,Nasdaq ,American Heart Association ,Executive Vice President ,Biopharmaceuticals Business Unit ,New England Journal ,Nature Medicine ,Rare Diseases ,Stroke Statistics ,Report From ,American Heart ,Eur Heart ,Scientific Sessions ,Global Burden ,Disease Study ,Heart Failure ,American College ,American Heart Association Joint Committee ,Clinical Practice ,Eurj Heart ,Disease Control ,Kidney Diseases ,